---
layout: post
title: "赛隆药业：注射用替加环素和注射用胸腺法新通过仿制药一致性评价"
date: 2022-04-15 16:06:34 +0800
categories: zhengquanshibao
tags: 证券时报新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002898" data-code="002898|0|2" data-code2="002898|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002898&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002898_0" data-code="K 002898|0|2" data-code2="K 002898|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>赛隆药业(002898)4月15日晚间公告，公司全资子公司湖南赛隆药业有限公司的注射用替加环素和注射用胸腺法新通过仿制药质量与疗效一致性评价。<br /></p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204152345116320>

[返回证券时报新闻](//finews.withounder.com/category/zhengquanshibao.html)｜[返回首页](//finews.withounder.com/)